Immune response to COVID-19 vaccination in hemato-oncology patients

Immune response to COVID-19 vaccination in hemato-oncology patients - ImV-HOng

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00027372

Enrollment

417

Registered

2022-01-11

Start date

2021-03-17

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hematooncological diseases

Interventions

Group 1: hemato-oncological patients Blood samples before and after vaccination (day 35 and day 120 after the first vaccination) of patients and healthy controls, who decided to be vaccinated close t

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: patients • age = 18 years • one of the following malignant diagnoses: - myeloid disorders (AML, MPN, or MDS) - lymphatic disorders (CLL, lymphoma, or MM) - malignant diseases treated with checkpoint inhibitors healthy subjects • age = 18 Jahre • willingness to or present appointment for covid-19 vaccination

Exclusion criteria

Exclusion criteria: patients • patients not willing to or unable to get vaccinated • patients with a duration of remission of = 5 years • patients unable to give consent healthy subjects • subjects not willing to or unable to get vaccinated according to recommendations of the Robert-Koch-Institut • subjects with a malignant disease and a duration of remission of < 5 years • subjects unable to give consent

Design outcomes

Primary

Measure	Time frame
humoral immune response to the covid-19 vaccine of patients with hemato-oncological diseases compared to healthy subjects on day 35 (+7) after initial vaccination	—

Secondary

Measure	Time frame
• humoral immune status: - before covid-19 vaccination (day 0 to -21) - day 120 (+14) after initial vaccination • cellular immune status before, on day 35 (+7) and day 120 (+14) after initial vaccination • immune response of hemato-oncological diseases: - myeloid disorders [acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN) and myelodysplastic syndromes (MDS)] - lymphatic disorders [chronic lymphocytic leukemia (CLL), lymphoma, multiple myeloma (MM)] - patients currently treated with checkpoint inhibitors • immune response of therapy versus „watch and wait“ • impact of patient and disease related factors on immune response • CRP and lymphocyte count in peripheral blood • post-marketing surveillance for collection of safety and tolerability data of the covid-19 vaccine in patients with hemato-oncological diseases and healthy subjects	—

Measure

Time frame

• humoral immune status: - before covid-19 vaccination (day 0 to -21) - day 120 (+14) after initial vaccination • cellular immune status before, on day 35 (+7) and day 120 (+14) after initial vaccination • immune response of hemato-oncological diseases: - myeloid disorders [acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN) and myelodysplastic syndromes (MDS)] - lymphatic disorders [chronic lymphocytic leukemia (CLL), lymphoma, multiple myeloma (MM)] - patients currently treated with checkpoint inhibitors • immune response of therapy versus „watch and wait“ • impact of patient and disease related factors on immune response • CRP and lymphocyte count in peripheral blood • post-marketing surveillance for collection of safety and tolerability data of the covid-19 vaccine in patients with hemato-oncological diseases and healthy subjects

—

Countries

Germany

Contacts

Public ContactHaifa Kathrin Al-Ali

Krukenberg Krebszentrum HalleUniversitätsklinikum Halle (Saale)

haifa.al-ali@uk-halle.de0345 557 7712

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 9, 2026